Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000521689 | SCV000618018 | uncertain significance | not provided | 2017-07-26 | criteria provided, single submitter | clinical testing | The K458Q variant in the CPT2 gene has not been reported previously as a pathogenic variant, nor as a benign variant, to our knowledge. The K458Q variant is observed in 37/10370 (0.36%) alleles from individuals of African background in the ExAC dataset, and no individuals were reported to be homozygous (Lek et al., 2016). The K458Q variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is not conserved across species, and in silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. We interpret K458Q as a variant of uncertain significance. |
Labcorp Genetics |
RCV001085292 | SCV000632586 | likely benign | Carnitine palmitoyltransferase II deficiency | 2024-01-25 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV001334222 | SCV001527011 | uncertain significance | Carnitine palmitoyl transferase II deficiency, severe infantile form | 2018-10-24 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Mayo Clinic Laboratories, |
RCV000521689 | SCV001715290 | uncertain significance | not provided | 2023-04-21 | criteria provided, single submitter | clinical testing |